The ''Hamburg Life After Cancer Program'': Development, Implementation and Evaluation of a Structured Survivorship Program - Study Protocol of a Hybrid Effectiveness-Implementation Study
Abstract
BackgroundAdvances in multimodal oncological treatment have improved survival, resulting in a growing population of cancer survivors. Yet, many survivors experience physical and psychosocial late and long-term effects after completing active cancer treatment, highlighting the need for follow-up care that extends beyond tumor surveillance. However, structured survivorship programs addressing survivors broader needs and evidence on their effectiveness and implementation remain limited.
MethodsThis prospective, single-center, single-arm intervention study with an external control cohort aims to develop, implement, and systematically evaluate the Hamburg Life After Cancer Program. Applying a hybrid type 2 effectiveness-implementation design, the primary aim is to improve health-related quality of life (HRQoL) among program participants (n = 500), namely cancer survivors aged 18-65 years who completed primary treatment. Secondary objectives include improvements in various bio-psycho-social outcomes, as well as an exploratory comparison of HRQoL with an external control cohort receiving usual care (n = 250). Outcomes are assessed at baseline, 26 weeks and 52 weeks. Implementation is evaluated following a mixed-methods approach. The intervention comprises patient navigation, multidimensional assessment, survivorship consultations, an interdisciplinary survivorship board, individualized care plans, a survivorship handbook, educational sessions and peer-support. All study phases are guided by a participatory research approach involving patients and experts.
DiscussionFindings will contribute to the development of needs-based, feasible survivorship care models, improving HRQoL and providing holistic support for cancer survivors. The study design enables timely translation of the program into clinical practice and robust assessment of its effectiveness and implementation. However, the non-randomized design may limit causal inference and cannot fully exclude residual confounding or selection bias despite statistical adjustment. If shown to be effective and feasible, the program may serve as a standardized model for structured survivorship care in Germany.
Trial RegistrationClinical trial registration number: DRKS00035126, German Clinical Trial Register (date of registration: 27 August 2025).
Related
- Implementation of early child development and maternal mental health care package for forcibly displaced Myanmar population in Bangladesh refugee camps: a process evaluation and cost-effectiveness study
- Supporting implementation of the national standards for cancer survivorship care: development of the cancer survivorship maturity model (CSMM)
- Effectiveness and implementation of electronic decision support for adult vaccination in primary care: a mixed-methods quasi-experimental evaluation
- Improving the detection, assessment, management and prevention of delirium in palliative care units (the DAMPen-Delirium II study): protocol for an implementation-to-target Type III hybrid effectiveness-implementation cluster randomised-controlled trial, economic evaluation and process evaluation of the Creating Learning Environments for Compassionate Care-Palliative (CLECC-Pal) implementation strategy.
- Noise Cancelling Program: evaluating the implementation and effectiveness of a psychoeducational program for mental skills development in young athletes.
BibTeX
@misc{fuhres2026hamburg,
title = {{The ''Hamburg Life After Cancer Program'': Development, Implementation and Evaluation of a Structured Survivorship Program - Study Protocol of a Hybrid Effectiveness-Implementation Study}},
author = {H. Führes and J. von Grundherr and F. Wolters and M. Rutenkröger and A. Zapf and A.-K. Ozga and A. Möhl and O. Kodalle and H. Schulz and C. Bokemeyer and A. Letsch and I. Scholl and M. Sinn},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.11.26362829},
url = {https://www.medrxiv.org/content/10.64898/2026.09.11.26362829v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - The ''Hamburg Life After Cancer Program'': Development, Implementation and Evaluation of a Structured Survivorship Program - Study Protocol of a Hybrid Effectiveness-Implementation Study
AU - H. Führes
AU - J. von Grundherr
AU - F. Wolters
AU - M. Rutenkröger
AU - A. Zapf
AU - A.-K. Ozga
AU - A. Möhl
AU - O. Kodalle
AU - H. Schulz
AU - C. Bokemeyer
AU - A. Letsch
AU - I. Scholl
AU - M. Sinn
PY - 2026
DA - 2026/09/11
PB - medRxiv
DO - 10.64898/2026.09.11.26362829
UR - https://www.medrxiv.org/content/10.64898/2026.09.11.26362829v1
AB - BackgroundAdvances in multimodal oncological treatment have improved survival, resulting in a growing population of cancer survivors. Yet, many survivors experience physical and psychosocial late and long-term effects after completing active cancer treatment, highlighting the need for follow-up care that extends beyond tumor surveillance. However, structured survivorship programs addressing survivors broader needs and evidence on their effectiveness and implementation remain limited. MethodsThis prospective, single-center, single-arm intervention study with an external control cohort aims to develop, implement, and systematically evaluate the Hamburg Life After Cancer Program. Applying a hybrid type 2 effectiveness-implementation design, the primary aim is to improve health-related quality of life (HRQoL) among program participants (n = 500), namely cancer survivors aged 18-65 years who completed primary treatment. Secondary objectives include improvements in various bio-psycho-social outcomes, as well as an exploratory comparison of HRQoL with an external control cohort receiving usual care (n = 250). Outcomes are assessed at baseline, 26 weeks and 52 weeks. Implementation is evaluated following a mixed-methods approach. The intervention comprises patient navigation, multidimensional assessment, survivorship consultations, an interdisciplinary survivorship board, individualized care plans, a survivorship handbook, educational sessions and peer-support. All study phases are guided by a participatory research approach involving patients and experts. DiscussionFindings will contribute to the development of needs-based, feasible survivorship care models, improving HRQoL and providing holistic support for cancer survivors. The study design enables timely translation of the program into clinical practice and robust assessment of its effectiveness and implementation. However, the non-randomized design may limit causal inference and cannot fully exclude residual confounding or selection bias despite statistical adjustment. If shown to be effective and feasible, the program may serve as a standardized model for structured survivorship care in Germany. Trial RegistrationClinical trial registration number: DRKS00035126, German Clinical Trial Register (date of registration: 27 August 2025).
ER -